abstract |
Composition for use as a medicament in a combination therapy to treat or reduce the risk of contracting vaginal dryness, the composition comprising: a) a precursor of the sex steroids selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5 -eno-3β, 17β-dol, 4-androstene-3,17-dione and a prodrug that is converted in vivo into any of the previous precursors of sex steroids and b) a therapeutically effective amount of a selective estrogen receptor modulator which is a benzopyran derivative in which the prodrug converted in vivo into a precursor of sex steroids has the general formula: ** Formula ** in which X is selected from the group consisting of H-, ROC-, RCO2CHRa- and RbSO2- (R being selected from the group consisting of hydrogen, straight or branched chain (C1-C18) alkyl, straight or branched chain C2-C18 alkenyl, (C2-C18) alkynyl d e linear or branched chain, aryl, furyl, straight or branched chain (C1-C18) alkoxy, straight or branched chain (C2-C18) alkenyloxy, straight or branched chain (C2-C18) alkynyloxy, aryloxy, furyloxy and halogen or carboxyl analogs of the foregoing; Ra being hydrogen or (C1-C6) alkyl and Rb being selected from the group consisting of hydroxyl (or salts thereof), methyl, phenyl and p-toluyl); in which Y is the carbonyl oxygen or Y represents a β-OX (having X the same meaning as above) and α-H and in which the selective estrogen receptor modulator has the following formula: ** Formula ** |